An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia (NASDAQ: EXAI) will announce its Q2 2022 financial results on August 17, 2022, after market close. The company is hosting a conference call on August 18 at 1:30 p.m. BST to discuss the results and its drug development pipeline. With over 30 projects ongoing, Exscientia emphasizes its commitment to enhancing drug development through AI technology, aiming to deliver faster and more effective treatments. The conference can be accessed via the company's website or by phone.
Positive
Over 30 drug development projects underway utilizing AI technology.
Host of a conference call to discuss financial results and corporate strategy.
Negative
None.
Company to host conference call and webcast on August 18, 2022 at 1:30 p.m. BST / 8:30 a.m. ET
OXFORD, England--(BUSINESS WIRE)--
Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 17, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. ET on Thursday, August 18, 2022, to provide an overview of the Company’s pipeline and corporate strategy.
A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 30 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
When will Exscientia report its Q2 2022 financial results?
Exscientia will report its Q2 2022 financial results on August 17, 2022, after U.S. market close.
What time is Exscientia's conference call for Q2 2022 results?
The conference call for Exscientia's Q2 2022 results will be held on August 18, 2022, at 1:30 p.m. BST / 8:30 a.m. ET.
Where can I access the Exscientia conference call?
The conference call can be accessed via the 'Investors and Media' section of Exscientia's website or by dialing specific numbers provided in the press release.
What is the focus of Exscientia's pipeline?
Exscientia's pipeline focuses on developing precision-designed therapeutic candidates through AI technology.
What is Exscientia known for in the pharmaceutical industry?
Exscientia is known for its AI-driven approach to drug design and development, including the first functional precision oncology platform.
